Dividend Yield (Forward) 0.00% Total Yield — Company Profile Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates...
Starbucks customers will face new norm in stores after sales dip The coffee giant is eager to win back customers with a series of significant changes. SBUX Retail, Shopping Malls, Chain Stores News & Analysis 4 hours ago Peloton reports negative quarterly earnings but its stock is soaring ...
Top Market News Notable Calls On The Move Earnings News Energy Stock News Tech Stock News IPO News Market Data Earnings Calendar Currencies Cryptocurrency Prices Sectors Dividends Top Dividend Stocks Top Quant Dividend Stocks Dividend Ideas Dividend Quick Picks Dividend Strategy Dividend News - Funds Div...
Trade-Ideas: Cellectis (CLLS) Is Today's Weak On High Relative Volume Stock Trade-Ideas LLC identified Cellectis (CLLS) as a weak on high relative volume candidate CLLS Business News Videos Jun 16, 2016 11:19 AM EDT CEOs Should Set Tone for Corporate Culture Transparency between executive man...
Top Quant Dividend Stocks High Dividend Yield Stocks Top Dividend Stocks ETFs & Funds ETF Screener ETF Analysis ETF Guide Mutual Funds Closed End Funds Editors' Picks Dividends Dividend Stock News REITs Dividend Ideas Dividend Strategy Dividend Quick Picks Editors' Picks Analysis by Sector Energy Commu...
Stock Market Holidays & Hours After Hours Trading Portfolio Management Cryptocurrency Dividend Investing Portfolio Strategy Fixed Income Retirement IPO's Podcasts Video Hub Editors' Picks Stock Analysis Stock Ideas Long Ideas Stock Upgrades & Downgrades Editors' Picks Quick Picks & Lists Emerging Markets ...